BCIL - ETF AI Analysis
Top Page
Bancreek International Large Cap ETF (BCIL)
BCIL (Bancreek International Large Cap ETF) has a solid but not top-tier overall rating, driven mainly by strong, profitable holdings like Novartis, which combines healthy earnings, a stable balance sheet, and a reliable dividend, and Advantest, which adds growth and positive technical signals despite some valuation concerns. The fund’s rating is held back somewhat by names like Codan and Asics, where bearish price trends and potentially high valuations introduce more risk, and overall investors should be aware that several holdings show signs of being overbought or expensive, which could increase volatility.
BCIL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 90.30M
- Region
- Developed Markets
- Expense Ratio
- 0.80%
- Beta
- 0.73
- Issuer
- Bancreek
- Inception Date
- Mar 21, 2024
- Dividend Yield
- 0.74%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
BCIL Summary
BCIL, the Bancreek International Large Cap ETF, invests in big, well-established companies outside the U.S., aiming to give you broad global exposure without picking individual stocks yourself. It doesn’t track a specific index, but focuses on large international firms across many sectors, including industrials, consumer companies, and technology. Well-known names in the fund include SK hynix from South Korea and Novartis from Switzerland. Someone might invest in BCIL to diversify beyond their home market and tap into worldwide growth. A key risk is that international stock prices can rise or fall sharply, and currency swings can also affect your returns.
How much will it cost me?
This ETF has an expense ratio of 0.80%, which means you’ll pay about $8 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed rather than simply tracking an index, which generally costs more.
What would affect this ETF?
BCIL could benefit if developed markets outside the U.S. grow steadily, consumer spending remains healthy, and global demand supports its large-cap consumer, technology, and industrial companies like Dollarama, Novartis, and Advantest. On the downside, slower economic growth abroad, rising interest rates that pressure large international firms, or regulatory changes affecting sectors such as financials and utilities could weigh on the ETF’s future performance.
BCIL Top 10 Holdings
BCIL leans heavily on a handful of international large caps, with Codan and Advantest acting as key engines of recent gains thanks to their rising momentum and growth stories. Benefit Systems and Diploma are also pulling their weight, adding steady support from Europe. On the flip side, HUB24 has been dragging the fund, while Holcim and Italgas look more mixed and have recently lost some steam. Sector exposure is broadly spread across consumer, industrial, and tech names, and with all holdings outside the U.S., this ETF is a pure developed-markets ex‑U.S. play.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 KR:000660 | SK hynix Inc. | 4.57% | $4.05M | KRW 1033.53T | 149.65% | ―― |
 CH:NOVN | Novartis AG | 4.20% | $3.73M | CHF 244.89B | 35.30% | 80Outperform |
 JP:6857 | Advantest | 4.09% | $3.63M | JPY 24.32T | 56.53% | 75Outperform |
 IT:IG | Italgas S.p.A. | 4.02% | $3.57M | EUR 9.11B | -3.16% | 67Neutral |
 SE:TEL2.B | Tele2 AB | 3.96% | $3.51M | SEK 110.89B | 5.38% | 73Outperform |
 JP:7936 | Asics | 3.95% | $3.51M | JPY 3.26T | 23.51% | 61Neutral |
 AU:CDA | Codan Limited | 3.80% | $3.37M | AUD 10.85B | 62.88% | 59Neutral |
 KR:402340 | SK Square Co., Ltd. | 3.58% | $3.17M | KRW 118.08T | 219.22% | ―― |
BCIL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BCIL, the sentiment is Negative. The current price of 28.11 is below the 20-day moving average (MA) of 28.43, below the 50-day MA of 28.96, and below the 200-day MA of 28.69, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 42.92 is Neutral, neither overbought nor oversold. The STOCH value of 71.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCIL.
BCIL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BCIL | $28.11 | $29.00(3.17% Upside) | $90.30M | 0.80% | 59Neutral |
 INEQ | $39.03 | $46.42(18.93% Upside) | $92.71M | 0.45% | 66Neutral |
 RWIN | $27.29 | $32.29(18.32% Upside) | $20.54M | 0.42% | 66Neutral |
 LCIV | $26.10 | ― | $20.25M | 0.99% | 67Neutral |
 FFDI | $30.58 | $38.53(25.97% Upside) | $18.65M | 0.55% | 67Neutral |
 JINT | $24.96 | $34.41(37.85% Upside) | $10.06M | 0.35% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BCIL | Bancreek International Large Cap ETF | 28.11 | 0.09 | 0.33% | |
| INEQ | Columbia International Equity Income Etf | 39.03 | 4.88 | 14.29% | |
| RWIN | Rayliant NxtGen Multifactor International Equity ETF | 27.29 | 1.57 | 6.08% | |
| LCIV | Logan Capital International ETF | 26.10 | 1.27 | 5.11% | |
| FFDI | Fidelity Fundamental Developed International ETF | 30.58 | 0.88 | 2.95% | |
| JINT | Janus Henderson International Core Alpha ETF | 24.96 | -0.20 | -0.81% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.